Skip to main content

Day: August 2, 2021

Abcam to Acquire BioVision for $340 million

Written by Customer Service on . Posted in Mergers And Acquisitions.

CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) — Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) (“Abcam”, “the Company” or “the Group”), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlightsBioVision is a fast-growing innovator and distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell-based assay kits Brings one of Abcam’s large third-party suppliers in-house Accelerates Abcam’s strategic execution and focus on in-house innovation and products in the complementary biochemical...

Continue reading

Heineken Holding N.V. reports 2021 half year results

Written by Customer Service on . Posted in Public Companies.

Amsterdam, 2 August 2021 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) announces: KEY HIGHLIGHTSThe net result of Heineken Holding N.V.’s participating interest in Heineken N.V. for the first half year of 2021 amounts to €517 million Net revenue (beia) €9,971 million, +14.1% organic growth Net revenue (beia) organic growth per hectolitre +5.5% Consolidated beer volume organic growth +9.6% Heineken® volume +19.6% Operating profit (beia) organic growth +109.3% Net profit (beia) €896 million, +320.3% organic growth EverGreen strategy deployment at HEINEKEN has started Full year expectations unchanged: financial results to remain below 2019. FINANCIAL SUMMARY1IFRS Measures € million Total growth   BEIA Measures € million Organic growth2Revenue 11,970    7.3  %  ...

Continue reading

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Written by Customer Service on . Posted in Public Companies.

Geneva, Switzerland, August 2, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 ET / 07:00 PT) the same day. Title:                Addex Half-Year 2021 Financial ResultsDate:               August 5, 2021Time:               16:00 CEST (15:00 BST / 10:00 ET / 07:00 PT) Joining the Conference Call:1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in...

Continue reading

Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science

Written by Customer Service on . Posted in Public Companies.

Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) – Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. “It’s great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex and our research programs,” said Tim Dyer, CEO of Addex. “We look forward to his contribution to our pipeline as we advance multiple...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.